| Company | Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
GlaxoSmithKline plc
| LON
|
GSK
|
1,749.50
|
|
+7.50
(0.43%)
| 84,745.78M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
GlaxoSmithKline plc (ADR)
| NYSE
|
GSK
|
52.97
|
|
+0.24
(0.46%)
| 130,030.63M
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
IPG Investment Partners Group AG
| ETR
|
GSK
|
0.0000
|
|
|
|
|
|
IPG Investment Partners Group AG, formerly known as IPG Investment Partners
Group Wertpapierhandelsbank AG, is a Germany-based investment bank for ...
| |
| |
|
|
GlaxoSmithKline PLC
| FRA
|
GS7
|
20.49
|
|
+0.18
(0.90%)
|
|
|
|
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the
creation and discovery, development, manufacture and marketing of ...
| |
| |
|
|
Cyclacel Pharmaceuticals Inc
| NASDAQ
|
CYCC
|
3.25
|
|
+0.07
(2.20%)
| 27.41M
|
|
|
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the
immune system to treat cancer and other serious illnesses.
| |
| |
|
|
Cytokinetics, Inc.
| NASDAQ
|
CYTK
|
1.16
|
|
-0.02
(-1.69%)
| 169.90M
|
|
|
Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused
on the discovery and development of small molecule therapeutics that ...
| |
| |
|
|
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
| NASDAQ
|
CYCCP
|
7.65
|
|
-0.01
(-0.07%)
| 3.22M
|
|
|
|
|
|
CYCLACEL PHARM. DL-,001
| FRA
|
UXI2
|
2.46
|
|
+0.10
(4.10%)
|
|
|
|
|
|
|
CYTOKINETICS INC. DL-,001
| FRA
|
KK3
|
0.888
|
|
+0.014
(1.60%)
|
|
|
|
|
|
